Changing ethical issues in the treatment of spina bifida: A personal odysseyAlthough the experience of the author is limited to the United States, ethics is not so limited, and what is an ethical imperative in one country may not be in another. What is considered ethically acceptable in one era may, as is indicated in this chapter, may not be ethical in a different era. Each society, must through appropriate discussion, determine the moral and ethical standards which are appropriate and acceptable to that society at that time. This is not to say that there are not some standards which apply to all societies. The authors approach to this concept of changing moral and ethical acceptability is discussed further in Tough Decisions: a casebook in medical ethics. Chapters 14 and 15. Freeman, JM and McDonnell,K Mc. Oxford University Press, NY. 1987.

Autor: Freeman, John M.¹

Publikováno v: Mental Retardation & Developmental Disabilities Research Reviews. 1998, Vol. 4 Issue 4, p302-307. 6p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comorbidity of internalising disorders in children and adolescents with low IQ : an item response theory approach

Autor: Freeman, JM

The main purpose of the present study was to employ 2-parameter logistic item response theory modelling (2-PLM) to examine the internalising dimension, comprising diagnoses of common mood and anxiety disorders, within a low IQ (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64606355a271e981d5853b98cb5cb34a

Enrichment of adeno-associated virus serotype 5 full capsids by anion exchange chromatography with dual salt elution gradients.

Autor: Lavoie RA; BridgeBio Gene Therapy LLC, Raleigh, North Carolina, USA., Zugates JT; Shattuck Labs, Durham, North Carolina, USA., Cheeseman AT; Cytiva, Marlborough, Massachusetts, USA., Teten MA; BridgeBio Gene Therapy LLC, Raleigh, North Carolina, USA., Ramesh S; BridgeBio Gene Therapy LLC, Raleigh, North Carolina, USA., Freeman JM; BridgeBio Gene Therapy LLC, Raleigh, North Carolina, USA., Swango S; BridgeBio Gene Therapy LLC, Raleigh, North Carolina, USA., Fitzpatrick J; BridgeBio Gene Therapy LLC, Raleigh, North Carolina, USA., Joshi A; BridgeBio Gene Therapy LLC, Raleigh, North Carolina, USA., Hollers B; KBI Biopharma, Durham, North Carolina, USA., Debebe Z; Shattuck Labs, Durham, North Carolina, USA., Lindgren TK; BridgeBio Gene Therapy LLC, Raleigh, North Carolina, USA., Kozak AN; BridgeBio Gene Therapy LLC, Raleigh, North Carolina, USA., Kondeti VK; BridgeBio Gene Therapy LLC, Raleigh, North Carolina, USA., Bright MK; BridgeBio Gene Therapy LLC, Raleigh, North Carolina, USA., Yearley EJ; BridgeBio Gene Therapy LLC, Raleigh, North Carolina, USA., Tracy A; Code Biotherapeutics, Hatfield, Pennsylvania, USA., Irwin JA; BridgeBio Gene Therapy LLC, Raleigh, North Carolina, USA., Guerrero M; BridgeBio Gene Therapy LLC, Raleigh, North Carolina, USA.

Publikováno v: Biotechnology and bioengineering [Biotechnol Bioeng] 2023 Oct; Vol. 120 (10), pp. 2953-2968. Date of Electronic Publication: 2023 May 31.